Company intelligence / Profile preview

QioN

Hangzhou, Zhejiang, Chinaqiontech.com ↗

Ownership: Private
Development stage: Commercial

Overview

Qihan Biotech has advanced multiple gene-edited cell therapies into Phase 1 clinical trials, including CAR-NK and dual-targeted NK therapies for acute myeloid leukemia. The company leverages multiplexable genome editing to create immune-shielded allogeneic cells and xenogeneic organs, aiming to address cancer, organ failure, and other serious conditions. Recent milestones include NMPA approval of an IND application for a multi-locus gene-editing product targeting CD19-positive B-cell lymphoma.

Therapeutic areas: Oncology
Modalities: CAR-NK cell therapyiNKT cell therapyNatural killer cell therapyCell therapy (general)
Industry: Biotech

Partnerships

Zhejiang University (collaborator on clinical studies)

Beyond the preview

Go deeper on QioN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QioN.

Explore the full profile